Physician profile
Laura E Schemm
NPI 1073996997
$1,336.94
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,321 · 2022: $15.64.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $550.10 | 2021 | |
| Janssen Biotech, INC. | $251.20 | 2021 | |
| Janssen Scientific Affairs, LLC | $104.90 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $96.79 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $87.15 | 2021-2022 | |
| Qol Medical, LLC | $59.24 | 2021 | |
| Redhill Biopharma INC. | $54.56 | 2021 | |
| Merck Sharp & Dohme LLC | $48.40 | 2021 | |
| Nestle Healthcare Nutrition INC. | $38.73 | 2021 | |
| Intercept Pharmaceuticals, INC. | $32.71 | 2021 | |
| Ferring Pharmaceuticals INC. | $13.16 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Schemm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.